BioPhy launched its AI operating system that radically accelerates the identification and development of the most promising drug candidates. By combi...
Both of these biomarkers are included in the company’s commercially available Precivity™ blood tests, which help healthcare providers determine...
“The first patient dosed with an AdvanCell therapeutic candidate represents a major milestone for the Company, our scientists, clinical trial sites, ...
Product Sales Excluding Veklury Increased 5% Year-Over-Year to $6.4 billion Biktarvy Sales Increased 12% Year-Over-Year to $3.1 billion Oncology Sales In...
-Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and industrial-scale cell therapy manufacturing, an...
1,929 patients randomized in a pair of Phase 3 trials to evaluate oral simufilam in Alzheimer's disease dementia. Top-line results for on-going, 52-week...
QIAGEN announced the launch of the Microbiome WGS SeqSets, a comprehensive Sample to Insight workflow designed to provide an easy-to-use solution that maxi...
Phase II results demonstrated significant albuminuria reductions by up to 39.5% vs. placebo when BI 690517, a novel selective aldosterone synthase inhibi...
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced a new generation of its distributed liquid bi...
Under the terms of the option agreement, AbbVie has the option to acquire a co-exclusive license to develop, manufacture, and commercialize reproxalap in t...
Initial EVX-01 Phase 2 data confirms the strong Phase 1 results After undergoing EVX-01 treatment, a significant and continuous tumor reduction was ...
FDA approval based on robust Phase III data in which Cosentyx® (secukinumab) showed rapid relief from symptoms of hidradenitis suppurativa (HS) as ea...
Quantum Leap Healthcare Collaborative (QLHC) announces the enrollment launch for the Re-Evaluating Conditions for Active Surveillance Suitability as Treatm...
Revenue of $671 million; (6)% reported growth; (7)% organic growth; 1% non-COVID organic growth GAAP EPS of $0.08; Adjusted EPS from continuing oper...
© 2025 Biopharma Boardroom. All Rights Reserved.
